RMC Pharmaceutical Solutions Announces an Expansion of the
Board of Directors and a New “Bolt-on CMC” Service Offering
May 14th, 2009
RMC Pharmaceutical Solutions, Incorporated
Shareholders of RMC Pharmaceuticals Solutions, Inc. recently
approved the expansion of its Board of Directors and
appointed Dr. Mark Young and W. Todd Myers as additional
members to the Board. The move brings outside
directors to the company’s leadership, and adds invaluable
expertise and experience as RMC Pharmaceutical Solutions,
Inc. continues to build its brand and business. In
a related action, the shareholders unanimously elected
Dr. Scott Rudge to the position of Chairman of the
Board of Directors.
“I’m pleased to welcome Dr. Young and Mr. Myers to our leadership
team at RMC Pharmaceutical Solutions,” said Dr. Rudge. “These
gentlemen are very highly regarded in the biotechnology
and entrepreneurial pharmaceutical business space. Their
advice and guidance will help us to leverage and promote
our “Bolt-on CMC” services as we continue to grow and expand
our capabilities.” Timothy Joy, RMC Pharmaceutical
Solutions’ President and CEO said, “Our collaborations with
Mark and Todd have been very positive over the years. It
made sense to formalize these relationships and take full
advantage of their talents. Our clients will derive
extended benefits from their addition to our team.”
Dr. Young is an experienced executive specializing in process
development and manufacturing of biopharmaceutical products. He
started his career as a process development scientist with
large international pharmaceutical companies (Hoffmann LaRoche
and Upjohn), and then joined the biotech industry in 1985.
He has served as a Senior Vice President of three biotech
companies (Synergen, Protein Design Labs, ZymoGenetics)
and as Chief Operating Officer of Biomira. Dr. Young
received degrees at the University of Nebraska, Columbia
University, and The University of Michigan, all in Chemical
Engineering. He is currently a consultant, specializing
in bioprocess development and manufacturing issues.
W. Todd Myers, C.P.A., is a veteran financial executive
with significant management experience in both public and
private drug discovery/development companies. Mr.
Myers is currently a member of the Board of Advisors of
BioLaurus, Inc., a contract research organization specializing
in cutting edge molecular imaging and high content analysis
services for the biotechnology and pharmaceutical industry. He
also provides coaching and guidance to start-up life science
companies as an Entrepreneur-in-Residence at CONNECT,
a non-profit organization dedicated to creating and sustaining
the growth of innovative technology and life science businesses
in San Diego. Most recently, Mr. Myers was the Chief
Financial Officer of SGX Pharmaceuticals, Inc., a publicly-traded
biotechnology company focused on the discovery, development
and commercialization of innovative cancer therapeutics,
and was instrumental in the sale of SGX to Eli Lilly & Company
at a premium of 119% to its then-current trading price. Prior
to SGX, as the Director of Finance at CombiChem, Inc, a
publicly-traded computational drug discovery company, Mr.
Myers managed all financial operations and was the senior
financial representative on the team responsible for the
sale of the company to DuPont Pharmaceuticals. He
was also the Chief Financial Officer of FeRx Incorporated,
a privately-held, clinical stage company dedicated to the
development of oncology products, and has held positions
with Premier Inc. and with Ernst & Young LLP. Mr.
Myers received his B.S. in Accounting from the University
of Illinois.
About RMC Pharmaceutical Solutions, Inc.
RMC Pharmaceutical Solutions, Inc. is a privately-held provider
of expert services to the pharmaceutical, biotechnology,
medical device and food industries. The company
was founded by Timothy Joy and Scott Rudge in 2004
to provide comprehensive services to companies developing
products for the health care industry. Since
its inception, RMC Pharmaceutical Solutions has served
more than 50 different clients in North America, Europe
and Asia. More recently, RMC has rolled out its
“Bolt-on CMC” service offering. Bolt-on CMC support
provides an experienced integrated team to support
Chemistry, Manufacturing and Control areas such as
process, analytical and formulation development; quality
control/quality assurance; and oversight of GMP
manufacturing. As part of this service, clients
can access both the considerable expertise of the RMC
team, as well as physical assets, such as an analytical
and process development laboratory; document management
and storage; and advanced software tools. For
more information, please visit www.rmcpharma.com. |
